What is Alexion stock price?
Key Turning Points
| 52-Week High | 187.45 |
|---|---|
| Last Price | 182.50 |
| Fibonacci 61.8% | 154.01 |
| Fibonacci 50% | 143.68 |
| Fibonacci 38.2% | 133.35 |
Is Alexion Pharmaceuticals a good stock to buy?
Alexion Pharmaceuticals has received a consensus rating of Hold. The company’s average rating score is 2.20, and is based on 3 buy ratings, 12 hold ratings, and no sell ratings.
Will Alexion stock go up?
Will Alexion Pharmaceuticals stock price grow / rise / go up? Yes. The ALXN stock price can go up from 182.500 USD to 192.312 USD in one year.
What will happen to Alexion stock?
Trading of the new AstraZeneca shares on Nasdaq Stockholm is expected to commence on 22 July 2021. The Alexion shares will be delisted from the Nasdaq Stock Market and Alexion will terminate its registration under the U.S. Securities Exchange Act of 1934 as soon as practicable following completion of the acquisition.
Is Alexion being bought by AstraZeneca?
Recommended companies AstraZeneca has completed the acquisition of biopharmaceutical company Alexion Pharmaceuticals in a deal valued at $39bn. AstraZeneca has completed the acquisition of biopharmaceutical company Alexion Pharmaceuticals in a deal valued at $39bn.
What happens to my Alexion stock after merger?
The Alexion shares will be delisted from the Nasdaq Stock Market and Alexion will terminate its registration under the U.S. Securities Exchange Act of 1934 as soon as practicable following completion of the acquisition.
Did AstraZeneca buy Alexion?
AstraZeneca expects to complete its $39 billion acquisition of Alexion on July 21 after receiving the last regulatory clearance it needed, from the U.K. Competition and Markets Authority.
What drugs does Alexion make?
Its products include eculizumab (Soliris) with $4.064 billion in 2020 revenues and ravulizumab (Ultomiris) with $1.076 billion in 2020 revenues, both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa (Strensiq) with $731 million in …
Is Alexion a good company to work for?
Alexion is a great place to work and really focused on the patients needs. The Mission and Culture inspires all levels and areas of the company engaging employees on its continuous growth.
Is Alexion being bought out?
AstraZeneca today completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca.
Who bought out Alexion?
AstraZeneca’s
AstraZeneca’s proposed $39bn acquisition of rare disease therapy company Alexion Pharmaceuticals has passed a US Federal Trade Commission (FTC) review. Cambridge-based AstraZeneca (AZ) first announced its intention to buy out Alexion in December.
Is eculizumab a chemo drug?
Eculizumab is the generic name for the trade chemotherapy drug Soliris. In some cases, health care professionals may use the trade name Soliris when referring to the generic drug name eculizumab.